PTIX (Protagenic Therapeutics) Buildings And Improvements: $0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PTIX Protagenic Therapeutics Inc PTIX
26 GF Score
Price $1.06
! 2 Warning Signs
View Full Analysis

What is Protagenic Therapeutics Buildings And Improvements?

Protagenic Therapeutics PTIX +6.00% 26 Buildings And Improvements is $0.00 Mil as of Dec. 2025. GuruFocus rates PTIX with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Protagenic Therapeutics Buildings And Improvements Historical Data

* Premium members only.

The historical data trend for Protagenic Therapeutics's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protagenic Therapeutics Buildings And Improvements Chart

Protagenic Therapeutics Annual Data
Trend Jun14 Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Buildings And Improvements
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Protagenic Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Buildings And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
PTIX
26GF Score
Protagenic Therapeutics Inc PTIX
Buildings And Improvements is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protagenic Therapeutics Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.

What does a Buildings And Improvements of $0.00 Mil mean?
Protagenic Therapeutics (PTIX) has a Buildings And Improvements of $0.00 Mil as of Dec. 2025. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on Protagenic Therapeutics and its competitors.
Is Protagenic Therapeutics' Buildings And Improvements too high?
Protagenic Therapeutics' current Buildings And Improvements is $0.00 Mil. Overall, Protagenic Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Protagenic Therapeutics' Buildings And Improvements compare to SCNI and DCOY?
Protagenic Therapeutics' Buildings And Improvements of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buildings And Improvements for a Biotechnology company?
A good Buildings And Improvements depends on the Biotechnology industry context. However, Buildings And Improvements should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buildings And Improvements mean?
A high Buildings And Improvements can signal that a stock is expensive relative to its fundamentals. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on Protagenic Therapeutics and its competitors. Protagenic Therapeutics's current Buildings And Improvements is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagenic Therapeutics stock overvalued right now?
Protagenic Therapeutics (PTIX) has a current Buildings And Improvements of $0.00 Mil. The current Buildings And Improvements is $0.00 Mil. Protagenic Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buildings And Improvements calculated?
Buildings And Improvements is calculated from a company's financial statements. For Protagenic Therapeutics (PTIX), the current Buildings And Improvements is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Protagenic Therapeutics Business Description

Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
26GF Score

Get the complete analysis for PTIX

Buildings And Improvements is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.06
Price